| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Dipotassium glycyrrhizinate (0-400 μM, 4 days) suppresses the mRNA levels of atopic dermatitis-related genes (NELL2, CA2, AQP3 and HAS3 gene levels) in cells produced by IL-4 and IL-13 [1]. Dipotassium glycyrrhizinate (0-400 μM, 4 days) partially recovered the atopic dermatitis-like phenotype (spongy cell spaces) in an IL-4/IL-13-induced AD-like skin equivalent mouse [1]. 0-100 μM, 24 hours) reduces sunitinib-induced autophagy and cell death in CCC-HEH-2 cells [4].
|
|---|---|
| ln Vivo |
Dipotassium glycyrrhizinate (150 mg/kg, i.p.) raises cardiovascular GLP-1 levels and lessens type 1 diabetes symptoms brought on by streptozotocin (65 mg/kg, i.p.) [2]. (50 mg/kg, intraperitoneal injection, once daily for 4 weeks) prevents the development of prostatitis in a model of autoimmune inflammation caused by potassium iodide in rats [3]. Intraperitoneal injection of 50–200 mg/kg dipotassium glycyrrhizinate
|
| Animal Protocol |
Animal/Disease Models: Iodine-induced autoimmune thyroiditis mouse model [3]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection, one time/day, Results lasting for 4 weeks: diminished serum TgAb, HMGB1, TNF-α, IL-6, IL-1β levels. Reduce the prevalence and lymphocyte infiltration of thyroiditis and reduce the severity of thyroiditis. |
| References |
[1]. Lee SH, et al. Ameliorating effect of dipotassium glycyrrhizinate on an IL-4- and IL-13-induced atopic dermatitis-like skin-equivalent model. Arch Dermatol Res. 2019 Mar;311(2):131-140.
[2]. Wang LY, et al. Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 2017 Nov;95:599-604. [3]. Li C, et al. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling. Thyroid. 2017 May;27(5):722-731. [4]. Xu Z, et al. Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy. 2022 May;18(5):1152-1173. [5]. Gao L, et al. Glycyrrhizic acid alleviates bleomycin-induced pulmonary fibrosis in rats. Front Pharmacol. 2015 Oct 1;6:215. |
| Molecular Formula |
C42H60K2O16
|
|---|---|
| Molecular Weight |
899.1128
|
| CAS # |
68797-35-3
|
| Related CAS # |
Ammonium glycyrrhizinate;53956-04-0;Glycyrrhizic acid;1405-86-3
|
| SMILES |
[K+].[K+].O(C1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C(=O)[O-])O1)O[H])O[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C(=O)[O-])O1)O[H])O[H])O[H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])[C@@]([H])(C([H])([H])C([H])([H])[C@@]3(C([H])([H])[H])[C@]4(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]5(C([H])([H])[H])C([H])([H])C([H])([H])[C@@](C(=O)O[H])(C([H])([H])[H])C([H])([H])[C@@]5([H])C4=C([H])C([C@@]32[H])=O)C1(C([H])([H])[H])C([H])([H])[H]
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~55.61 mM)
DMSO : ~20.83 mg/mL (~23.17 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (111.22 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1122 mL | 5.5611 mL | 11.1221 mL | |
| 5 mM | 0.2224 mL | 1.1122 mL | 2.2244 mL | |
| 10 mM | 0.1112 mL | 0.5561 mL | 1.1122 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
